Adagrasib, also known as MRTX849, is an investigational small molecule inhibitor of KRAS G12C, a mutated form of the KRAS protein commonly found in various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer. Chemically, it is designed to specifically target the mutant KRAS protein, which drives uncontrolled cell growth and tumor progression. Adagrasib works by irreversibly binding to the KRAS G12C protein, inhibiting its activity and disrupting downstream signaling pathways involved in cancer cell proliferation and survival. Clinical trials have shown promising results, with adagrasib demonstrating antitumor activity in patients with KRAS G12C-mutant cancers, particularly those who have previously failed standard therapies. Ongoing research aims to further evaluate its safety, efficacy, and potential as a targeted therapy for KRAS-driven malignancie
Buy high quality Adagrasib from Chemicea Pharmaceuticals. Chemicea Pharmaceuticals is one of the leading manufacturer and exporter of Adagrasib.